This study is testing a new medicine called DS-1062a on people with advanced solid tumors, like non-small cell lung cancer (NSCLC), who haven't been cured by other treatments. It's the first time this medicine is being used in humans. A solid tumor is a mass of tissue that can be cancerous or non-cancerous. The study has two parts:
- Dose Escalation: Finding the safest dose of DS-1062a.
- Dose Expansion: Checking the safety of DS-1062a in other tumors.
The study will last about 6 years and take place in the United States and Japan. People can stay in the study as long as they benefit from the treatment and don't have bad side effects or their disease worsens. A sub-study will compare the effectiveness of steroid vs. non-steroid mouthwash to prevent mouth sores from the treatment. About 76 people will join this part.
- Study duration: approximately 6 years.
- Locations: United States and Japan.
- Sub-study involves about 76 participants.
How understandable was the trial content above?
Hard to understand
Easy to understand